Mr. Oren Shuster reports

IM CANNABIS ANNOUNCES APPOINTMENT OF SHMULIK ARBEL TO BOARD OF DIRECTORS

IM Cannabis Corp. has appointed Shmulik Arbel to the company's board of directors, effective Sept. 9, 2024. Mr. Arbel brings a wealth of experience in strategic plans that drive profitability as well as finance and corporate governance, further strengthening the company's commitment to driving growth while focusing on sustainable profitability.

"We are thrilled to welcome Shmulik to our board of directors," said Oren Shuster, chief executive officer of IM Cannabis. "Shmulik's extensive international experience at Leumi, coupled with his proven track record in banking and finance will be invaluable as we continue to deliver on our strategic initiatives."

Mr. Arbel retired as deputy chief executive officer from Leumi, Israel's largest banking group, in April, 2023, where he was instrumental in business growth and leading the service revolution. With over 25 years of experience at Leumi, Mr. Arbel has held senior roles throughout the organization, such as head of retail banking, head of the corporate division and chairman of Leumi U.K. With key roles in Israel, New York and London, Mr. Arbel has a wide view on international business.

"I am honoured to join the board of directors at IMCC," said Mr. Arbel. "I look forward to leveraging my experience in banking and finance, providing guidance as IMCC continues to establish itself as the go-to brand in the cannabis world. I look forward to contributing to the company's growth."

Mr. Arbel holds a BA and MBA from Tel Aviv University.

About IM Cannabis Corp.

IM Cannabis is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The company has focused its resources to achieve sustainable and profitable growth in its highest-value markets -- Israel and Germany. The company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the company strives to amplify its commercial and brand power to become a global high-quality cannabis player.

The IM Cannabis ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The company also operates medical cannabis retail pharmacies, on-line platforms, distribution centres and logistical hubs in Israel that enable the safe delivery and quality control of IM Cannabis products throughout the entire value chain. In Germany, the IM Cannabis ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.

We seek Safe Harbor.